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INTRODUCTION
IR to open-label Gocovri treatment at enrollment. c Two of the 9 patients who died during the trial discontinued study drug due to AEs and died subsequently (4 and 15 days later). d This patient who discontinued for unwilling to proceed/consent withdrawn was noted to have an AE leading to withdrawal in safety reporting. e Discontinuations for "other" reasons were mostly administrative or resulted from other medical issues. In the Continuing Gocovri group the discontinuations were: site closure (n = 3), underwent DBS surgery (n = 3), dyskinesia upon taper (n = 1), physician decision (n = 1), unable to complete visits per protocol (n = 1). In the Placebo Group they were: lack of efficacy (n = 1), patient relocation (n = 1), DBS group: site closure (n = 1), worsening dyskinesia (n = 1). AE, adverse events; DBS, deep brain stimulation; eGFR, estimated glomerular filtration rate; IR, immediate-release.
with an additional 5 discontinuing due to low eGFR 264 (protocol-mandated withdrawal). Nine patients (4%) 265 died during the study; none (0%) of the deaths were 266 considered by the investigator as related to study 267 drug. Figure 2 8 (13.3%) 5 (6.4%) 4 (16.7%) 4 (6.6%) 21 (9.4%) Livedo reticularis 6 (10.0%) 5 (6.4%) 3 (12.5%) 6 (9.8%) 20 (9.0%) On and off phenomenon 7 (11.7%) 4 (5.1%) 4 (16.7%) 3 (4.9%) 18 (8.1%) Dry mouth 4 (6.7%) 6 (7.7%) 4 (16.7%) 3 (4.9%) 17 (7.6%) a Includes all preferred terms with an incidence ≥7.5% among all patients. AE, adverse event; DBS, deep brain stimulation; SAE, serious adverse event. The list includes all preferred terms reported in more than 1 patient. Note: The reasons provided for the 9 deaths that occurred during the trial were: "natural causes" (study day 661), cardiac arrest (day 190), myocardial infarction (day 55), arrhythmia (day 473), pneumonia (day 99), Clostridium difficile sepsis (day 425), Pseudomonal sepsis (day 570), septic shock (day 508), and sepsis (day 414). None were considered related to study drug by the investigators. DBS, deep brain stimulation; MI, myocardial infarction. Table 5 . Recorded levodopa doses were the same as baseline for 109 patients (64.9%) at week 52 and 69 patients (51.5%) at week 100 (not shown on graph). Mean (SD) changes from baseline in MDS-UPDRS Part IV total score to weeks 52 and 100, respectively, were -0.9 (4.0) and -1.4 (4.6) for those who had an increased levodopa dose (n = 39 and n = 44), -2.8 (4.0) and -2.6 (4.2) for those who had no change (n = 105 and n = 66), and -2.3 (2.9) and -1.8 (2.8) for those who had a decreased levodopa dose (n = 19 and n = 20) compared to baseline. MDS-UPDRS assessments were not available for 5 patients at week 52 and for 4 patients at week 100. Week 52 N 4 7 5 5 1 2 5 1 Part I 11.5 (6.6) b 10.0 (5.9) c 9.9 (4.4) 9.9 (5.8) Part II 14.2 (7.6) 13.4 (7.3) 16.1 (10.9) 14.6 (6.9) Part III 27. 
